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ABSTRACT 
A plethora of biological barriers, intended to defend tissues and cells against external influences, stand 
in the way of efficient nucleic acid delivery by non-viral nanoplexes. Even when nanoplexes successfully 
evade extracellular barriers and reach their target cell, many intracellular barriers remain to be 
conquered. These include overcoming the plasma membrane, evading endosomal 
compartmentalization, and in some cases crossing the nuclear envelope. At the same time, exocytosis, 
autophagy and cytoplasmic degradation of the cargo should be avoided. Currently, there is a growing 
appreciation that the interaction of nanoplexes with these barriers should be understood in detail in 
order to rationally design a second generation of non-viral nanoplexes, capable of overcoming these 
many hurdles. Studying intracellular biobarriers is, however, quite challenging and specialized methods 
are constantly being developed. In this review, we present an overview of established as well as 
emerging techniques and assays that are currently available to the experimentalist to study nanoplex-
barrier interaction, with a focus on quantitative methods. 
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1. INTRODUCTION 
Gene therapy is defined as the delivery of therapeutic genes to target cells in order to replace or 
counteract a malfunctioning gene and has emerged as a promising strategy to cure a wide variety of 
inherited or acquired diseases at their genetic roots [1–4]. Besides the delivery of pDNA, several other 
nucleic acids (NAs), such as mRNA, siRNA and miRNA, have emerged as promising tools to modulate 
protein expression levels [5]. A fundamental challenge for successful delivery of these NAs lies within 
the engineering of delivery vectors that are both safe and effective [6]. On the one hand, viral vectors 
offer great efficiency in transfecting host cells, but unfortunately they suffer from several safety 
concerns including immunogenicity, cytotoxicity and the possibility for insertional mutagenesis. On the 
other hand, non-viral vectors have attracted substantial attention due to their advantages in terms of 
safety (reduced immunogenicity and no risk for insertional mutagenesis), lower costs, ease of 
production and ability to carry larger payloads [6–9]. Non-viral or synthetic vectors are typically based 
on cationic lipids and/or polymers that complex negatively charged NAs to form nanoplexes (NPls) 
[1,10,11]. However, despite decades of research, the success of non-viral vectors in clinical trials 
remains limited due to their poor efficiency in navigating through various biological barriers[6–8]. 
Biological barriers for non-viral gene therapy are typically divided into two categories: extracellular 
(EC) and intracellular (IC) barriers. In short, EC barriers need to be overcome prior to reaching the 
target cell. In Figure 1, the barriers after systemic administration are shown. These include endo- and 
exonuclease activity in the blood circulation, interaction with blood components, activation of the 
immune system, surpassing endothelial barriers and migration through the extracellular space. It must 
be mentioned that topical administration (e.g. pulmonary and oral routes) are also intensively explored 
for gene therapy. Here, the EC barriers are epithelial and extra factors such as the presence of mucus 
and surfactant play an important role. Together, these EC obstacles can lead to cargo degradation, 
rapid clearance of NPls or NPl immobilization, thereby rendering them ineffective [1,2]. Once past the 
EC barriers, several IC barriers obstruct the way to efficient gene delivery. First, in order to reach the 
IC environment, NPls need to cross the plasma membrane [2,12,13]. Although physical methods, such 
as photoporation, electroporation or sonoporation, are sometimes used to provide direct access to 
the cell cytoplasm [7,14,15], non-viral NPls usually gain entrance to the cell by endocytosis [5,16]. 
Following endocytic uptake, NPls are localized in early endosomes which mature via late endosomes 
into endolysosomes. This maturation is accompanied by intraluminal acidification and activation of 
various degradative enzymes [5]. Hence, using endocytosis as a way to enter the cell gives rise to an 
additional barrier: escaping endosomal confinement before enzymatic degradation of NAs in the 
endolysosomes. Moreover, NPl excretion from the cell via exocytosis may happen, further reducing 
gene delivery efficiency [17]. Even if endosomal escape happens, the NAs (whether still complexed to 
the vector or not) reside in the cytosol where they have to avoid being cleared from the cell by 
autophagy or being degraded by cytoplasmic nucleases. Furthermore, the kinetics of cargo release 
from the carrier is an important consideration, since vector unpacking has been reported as another 
bottleneck for efficient transfection. Finally, while NAs such as siRNA, mRNA and miRNA have their site 
of action in the cytosol, pDNA needs to be delivered to the nucleus in order to be effective, thereby 
making the nuclear envelope a major barrier as well [2,12,13,18]. 
There is a growing appreciation that understanding how non-viral NPls behave at each of these IC 
barriers is necessary to rationally design more efficient NPls [19–21]. Hence, the ability to visualize and 
reliably quantify the interaction of NPls with these biological barriers is crucial [21]. However, studying 
IC barriers has been proven quite challenging, not in the least because of the small size and low 
quantity of NPls in the cell. In this review, it is our aim to provide an overview of the entire toolbox 
that is available to study the different IC barriers in an in vitro setting. In this regard, we will discuss 
several well-established techniques, as well as emerging state-of-the-art techniques that provide 
exciting new possibilities. We first provide information on barrier-specific physiology and elaborate on 
the role these barriers play during the process of transfection with NPls. Next, we will present assays 
and techniques that are available to evaluate interaction of NPls with these barriers, including a 
discussion on their advantages and drawbacks. It is important to note that a considerable amount of 
techniques discussed in this review were developed using naked nanoparticles (NPs). Since the 
developed method is generally independent of the cargo, the methods discussed in this review are all 
considered to be applicable to study nanomedicines and more specific nanoplexes. Finally, we will 
elaborate on the gaps that remain present up to date and discuss the implementation of available 
techniques to boost the field in the future. 
 
*Vector unpacking could also occur inside nucleus or endosomes. 
Figure 1 Overview of extracellular (EC) and intracellular (IC) barriers for non-viral gene therapy after systemic 
administration. Several nucleic acids (NAs; e.g. pDNA, mRNA, siRNA, miRNA) can be incorporated in nanoparticles (NPs) in 
order to modulate protein expression levels. Upon systemic administration, several EC barriers are encountered: nucleases 
can lead to degradation of the NAs, opsonization of the NP can cause activation of the mononuclear phagocyte system (MPS) 
which can lead to degradation of the NPs and their cargo or to unwanted immune responses as a consequence of cytokine 
release. Also, extravasation poses an additional barrier for NPs to reach their target cells. Once NPs reach their target cell, 
there are several IC barriers standing in the way of transfection. First of all, the plasma membrane must be overcome in order 
to ensure cellular entry, which for NPs is usually accomplished by endocytic uptake. After endocytosis, NPs are still physically 
separated from the cytosol as they reside in endosomal vesicles. In order to gain access to the cytosol, the NPs must escape 
the endosomal pathway before the cargo is degraded in the lysosomes. Additional to lysosomal degradation, endocytosed 
NPs should avoid being recycled back to the EC environment via exocytosis or endocytic recycling. After reaching the cytosol, 
several other barriers are to be avoided including autophagy and cytoplasmic degradation. Finally, pDNA should be delivered 
into the nucleus, requiring passage across the nuclear envelope. Overall, vector unpacking represents an extra barrier since 
the cargo must be free from its vector in order to interact with its IC target. This figure was based on [6]. 
2. INVESTIGATING SPECIFIC INTRACELLULAR BARRIERS 
2.1. Cellular uptake 
Once NPls reach their target site, they have to ensure cellular uptake by traversing the plasma 
membrane. The amphiphilic properties of this lipid bilayer make it an efficient barrier and gatekeeper. 
It provides protection to the IC components from the surrounding environment, allows to maintain 
homeostasis and is involved in controlling the entry and exit of nutrients and charged small molecules 
[22]. Although several methods have been reported for cellular uptake, the dominant mechanism for 
NPl cell entry is endocytosis [5,16], which can be subdivided in many different endocytic pathways (as 
discussed in several excellent reviews [23–25]). After endocytic vesicles pinch off from the plasma 
membrane, they fuse with early endosomes from where the cargo is trafficked to different IC locations 
[21,22]. The understanding and quantification of cellular entry is of crucial importance, not only 
because efficient cellular entry is a prerequisite for effective gene delivery but also because the various 
endocytic pathways and subsequent vesicle trafficking have been shown to strongly affect NA delivery 
efficiency [26,27]. As there may be a link between the endocytic pathway and the final transfection 
efficiency, it is not only important to study the total amount of NPl uptake, but also the way they are 
internalized. Both will be discussed in detail in the following paragraphs. 
2.1.1. Evaluation and quantification of cellular uptake efficiency 
Investigating cellular uptake can be carried out qualitatively (yes or no) or quantitatively (amount of 
uptake). Even though in some cases qualitative determination of uptake might be sufficient, 
quantitative determination clearly is more informative and allows to compare uptake efficiencies 
between cell lines or between different particles. However, before one can quantify cellular uptake, 
one has to think about how to characterize and quantify NPls: by mass, surface area or particle number. 
All three metrics have been employed in the past, depending on experimental conditions and the 
method used. While mass concentration is convenient and frequently used in environmental risk 
assessment, surface area is considered a more suitable metric when studying interaction with 
biological interfaces, since these interactions are proportional to the surface area. However, 
quantification by particle number better reflects the particulate nature of NPls and would, if combined 
with size distribution information, be the metric of choice for quantification of NPls in biological 
systems [28–30]. Cellular uptake of NPls has been studied extensively over the last decades, resulting 
in a large amount of methods available for evaluation of NPl internalization. 
Flow cytometry allows (semi)quantification of cellular uptake in a large number of individual cells at 
high throughput and is therefore the most frequently used method to study NPl uptake in cells [31,32]. 
In this technique, size, granularity and multicolor fluorescent features of single cells passing through a 
light source in a fluid stream are measured [33,34]. In a typical experiment, cells are incubated with 
fluorescently labeled NPls for a certain amount of time, after which the total fluorescence per cell is 
determined, which is assumed to be proportional to the number of internalized NPls. However, several 
limitations should be considered when using this technique. First of all, being a non-confocal 
technique, flow cytometry cannot distinguish between fluorescence coming from inside the cells or 
fluorescence arising from NPls that are merely attached to the outer cell surface. Yet, for NPl uptake 
studies, one is interested specifically in the fluorescence coming from actually internalized NPls [35]. 
In order to aid in the differentiation of internalized vs membrane-attached NPls, various strategies 
have been developed. The most widely used strategy is the addition of fluorescence quenchers, such 
as Trypan Blue, that can be added to the flow medium to quench extracellular fluorescence [36,37]. As 
a more specific alternative, Liu et al. developed a specific hybridization internalization probe (SHIP) 
assay where a fluorescent internalization probe (FIP) is incorporated into the nanoparticle (NP). Once 
the incubation time with the NPs is completed, a quenching probe (QP) is added. The QP hybridizes to 
the FIP and quenches its fluorescence on the cell surface. As the QP is unable to quench internalized 
FIP (no access) or other surface markers (no hybridization), fluorescence is detected only from 
internalized NPs (Figure 2A-B). Although the applicability of this sensor was demonstrated on the 
internalization of transferrin, this technique is also applicable to any type of NP with any type of cargo 
[38]. Another approach is to try to remove cell-bound NPls by interfering with NPl-cell interactions or 
via the actual destruction of membrane-bound particles. In this regard, Braun et al. used a NP probe 
that comprises a fluorescently labeled polyethylene glycol (PEG) around a fluorescence-enhancing 
silver NP (AgNP) core. After incubation of the cells with these NPs, an etching solution is added to the 
cells consisting of a mixture of hexacyanoferrate (HCF) and thiosulphate (TS). HCF is used to oxidize 
Ag0 to Ag+, while TS clears away the newly formed Ag+ ions. In this way, the core of the NP dissolves 
and the labeled components are released from etched AgNPs, thereby losing their fluorescence 
enhancement. Since both HCF and TS are charged molecules, they do not readily diffuse through cell 
membranes, thus protecting internalized AgNPs from being etched (Figure 2C-D) [39]. This etching 
technique was also reported in order to determine the cellular internalization of AuNPs and should be 
applicable for a myriad of NPs and cargos, as long as there is a suiting etching solution available that 
does not induce high levels of cellular toxicity [40]. Complete destabilization of the interaction between 
the NP and the cell can be realized by extensive washing with NaOH [41] or an acidic buffer [42]. 
Alternatively, when evaluating cellular uptake based on labeled cargo, polyanions (e.g. heparin) are 
frequently used to competitively displace the labeled NA from the carrier, followed by removal through 
washing [43]. Another possibility is to estimate the amount of membrane-attached NPls via inhibition 
of active uptake of NPls at 4°C [44]. The fluorescence measured from those cells can be used to correct 
the total measured fluorescence of the cells incubated at 37°C (having membrane-bound + internalized 
NPls) in order to correctly estimate the fraction of internalized NPls. One could also use non-cell 
penetrating reagents to achieve a double-labeling of the membrane-bound NPls vs single-labeling of 
internalized NPs. In this regard, Ogris et al. labeled pDNA with YOYO-1 prior to complexation and added 
TOTO-3 after the addition of complexes to the cells. Since TOTO-3 also interacts with pDNA and is 
unable to penetrate the plasma membrane, EC pDNA is double-stained and IC pDNA is only stained 
with YOYO-1. Cells were then measured via flow cytometry and data were analyzed to render a ratio 
of fluorescence intensities on a single-cell level, which is indicative of the binding and internalization 
kinetics of the NPls [45]. On the same note, Smirnov et al. incubated cells with fluorescent particles 
and afterwards exposed the cells to an antibody, labeled with a different fluorophore, targeted to the 
particles (Figure 2E). Next, using imaging flow cytometry, they quantified the number of EC (double 
fluorescent) and IC (single fluorescent) particles per cell, from which particle internalization was 
determined. Even though the authors applied this protocol to examine the binding and internalization 
of a pathogenic bacterium into neutrophils, it should be applicable to evaluate any cell type and NPl of 
interest that can be recognized using antibodies or alternatives such as streptavidin-biotin complexes 
[35]. As a second issue, flow cytometry uptake measurements are usually reported in arbitrary 
fluorescence units. However, ideally one would like to convert these values to particle numbers 
[28,29]. To this purpose, various calibration methods have been reported. For instance, Summers et 
al. were able to quantify the number of quantum dots (QDs) internalized per cell through calibration 
of flow cytometry measurements to EM data [46]. Also fluorimetry has been used to relate 
fluorescence intensities to NP numbers, but in this case NPs with a narrow size distribution and fixed 
amount of labels are needed [47]. For the quantification of internalized fluorescently labeled plasmids, 
flow cytometry can be calibrated with qPCR [48]. Bishop et al. transfected human primary glioblastoma 
cells with poly(beta-amino ester) NPls containing Cy3 labeled eGFP pDNA. Thanks to the qPCR vs 
fluorescence calibration curve, the amount of Cy3 fluorescence could be converted to number of 
plasmid copies per cell [20]. A third important issue with flow cytometry has to do with the use of 
fluorophores to label NPls which may alter the way in which NPls interact with cells [20,49]. As such it 
may be prudent to compare results obtained with labeled and non-labeled NPls to estimate to which 
extent the NPl label may influence the transfection process. Furthermore, it must be noted that the 
measured fluorescence intensities are not always proportionate to cellular uptake since several NPs 
are able to quench fluorescence, which could potentially lead to the loss of fluorescence [50,51]. Also, 
the intensity might be dependent on environmental properties, such as the pH-dependent 
fluorescence of FITC fluorophores. Several fluorescent labeling strategies – with their own pros and 
cons – are available for NAs [52,53]. There are of course particular types of NPls, such as NPl based on 
AuNPs, AgNPs or TiO2 NPs, whose uptake could be determined to some extent without the need to 
use fluorescent labels. Due to their strong light scattering properties uptake measurements can be 
based on the change in side-scattered light (SSC) [54]. 
 
Figure 2 Strategies to distinguish between membrane-bound and internalized particles during classical uptake studies using 
flow cytometry. (A) Liu and coworkers developed a specific hybridization internalization probe (SHIP) to differentiate 
between membrane-attached and internalized NPs. The NP is labeled with a fluorescent internalization probe (FIP), which 
consists of a DNA strand with a fluorophore attached. Once the cells have been incubated with the NP, a quenching probe 
(QP) is added to the transfection medium. The QP is complementary to the sequence of the FIP, which enables it to hybridize 
to the FIP. Once the hybridization with the QP is completed, the fluorescence of the FIP is quenched by the QP. Since the QP 
is unable to migrate through the cellular membrane, fluorescence is detected only from internalized FIP. (B) Confocal images 
showing the efficiency of the SHIP assay. NPs are added at 37°C to allow active uptake of NPs, with (upper images) or without 
(lower images) the addition of the QP. Images A and B adapted with permission from [38]. © 2013 WILEY-VCH Verlag GmbH 
& Co. KGaA, Weinheim. (C) Schematic representation of fluorescently labeled AgNPs that are attached to the membrane and 
internalized into the cell. The brightness of the dye is enhanced by the local plasmonic field of intact AgNPs. After incubation, 
an etching solution is added to the cells which dissolves the Ag core of membrane-bound particles. Upon dissolution of the 
core, the plasmonic enhancement is lost. Internalized particles remain intact since the etching solution is unable to diffuse 
through the cell membrane. (D) Confocal microscopy images of cells incubated with AgNPs (green) and membrane stain (red) 
show how AgNPs are selectively retained in the cells after etching (right). Extracellular particles appear as green dots in the 
pre-etched image on the left (indicated by the white arrows) and are selectively removed after etching (right). Scalebar 
represents 15 µm in the main images and 2 µm in the insets. Images C and D were adapted with permission from Springer 
Nature Nature Materials [39] © 2014 (E) This figure depicts the general mechanism, developed by Smirnov et al. with N. 
gonorrhoeae as a particle on neutrophils. The protocol includes the addition of labeled antibodies to non-permeabilized cells 
that have been previously exposed to fluorescently labeled particles. Since the antibodies are unable to penetrate into the 
intracellular environment, the internalized particles will be single fluorescent, while external (membrane-bound) particles 
will have a double-fluorescent labeling.  
A second well-established technique to evaluate NPl uptake inside cells that is often used in 
conjunction to flow cytometry is light and fluorescence microscopy. This technique has proven to be 
extremely useful to study NPl distribution and qualitative uptake [55–58] and is also – to a minor extent 
– used to quantify cellular uptake of NPls [59,60]. Quantification of NPl uptake via light microscopy is, 
however, not that straightforward. While the total fluorescence per cell could be quantified if cells can 
be segmented reliably in the images, optical microscopy does not possess the necessary resolving 
power to detect single NPls, a key requirement for the quantification of particle numbers [28,61]. 
Recently, so-called “super-resolution” microscopy techniques have emerged that go beyond the 
diffraction limit and reach a resolution of <100 nm. Van der Zwaag et al. reported on the use of 
stochastic reconstruction microscopy (STORM) to extract quantitative information about the size, 
number and positioning of ovalbumin-loaded polystyrene NPs inside HeLa cells, while Peuschel et al. 
used stimulated emission depletion microscopy (STED) to quantify the uptake of unloaded silica NPs 
in A549 cells [26,62]. These promising results confirm that super-resolution microscopy can be used 
successfully in the quantification of cellular uptake on a single particle level.  
Due to the small de Broglie wavelength of accelerated electrons, electron microscopy (EM) provides 
superior spatial resolution (<0.2 nm for TEM; ± 1 nm for SEM) and is the technique of choice when it 
comes to resolving structures that are below the optical resolution limit [22,63,64]. Thus, EM is 
frequently used as a third technique to evaluate [65–69] or quantify [70–72] cellular uptake. Rothen-
Rutishauser et al. compared uptake of AuNPs in A549 cells via CLSM and TEM. AuNPs can be easily 
detected by TEM because of their high electron density and by CLSM due to the addition of the red 
fluorescent marker ATTO 590. Quantification via TEM resulted in the total number of internalized NPs 
since TEM, in contrast to CLSM, provides enough spatial resolution for detection of single NPs [73]. In 
order to downsize the complicated and time-consuming sample preparation that accompanies EM, 
liquid EM is regarded as an emerging field since it can eliminate some of the steps that are required 
for sample preparation in classic EM [74]. Peckys and de Jonge used a liquid-STEM approach to study 
live fibroblast cells with AuNPs using a microfluidic chamber. Since their approach can be used to study 
whole cells with a thickness up to ± 10 µm, the need for sectioning is excluded and only minimal sample 
preparation is required [75]. In 2014, Peckys and de Jonge performed imaging of whole cells in a fully 
hydrated state using environmental scanning electron microscopy (ESEM), resulting in a sample 
preparation time that is comparable to that for light microscopy [76]. Alternatively, volume restrictions 
may be eliminated by the use of focused ion beam scanning electron microscopy (FIB-SEM), which 
continuously sections matrix-embedded cells using an ion beam, thereby making 3D SEM images 
possible [54,72]. Apart from volume restrictions and time-consuming sample preparation, another 
issue that is often encountered in EM imaging is low contrast. Indeed, the NPl of interest can only be 
seen if the carrier has sufficient contrast compared to the biological material. Inorganic NPs like gold 
NPs and superparamagnetic iron oxide NPs can be distinguished easily, but organic NPs usually need 
contrast enhancing agents in order to be visualized [77]. 
Among the analytical techniques, one could determine cellular uptake by measuring the fluorescence 
intensity of a cell-lysate after incubation with fluorescently-labeled NPls [78]. However, since this 
technique also does not discriminate between membrane-bound and internalized NPls, one should 
find a way to distinguish the two forms, as discussed above. Furthermore, this technique provides 
information on a population level instead of on a single-cell level. Alternatively, inductively coupled 
plasma mass spectrometry (ICP-MS) methods are frequently used to quantify cellular uptake of NPs 
and NPls [79–82]. In ICP-MS the sample is ionized and its elemental composition is analyzed via MS. 
Alternatively, the ionized sample can be analyzed by atomic emission spectrometry (ICP-AES), also 
referred to as optical emission spectrometry (ICP-OES) [29,83,84]. Both methods can be used for high-
throughput analysis of a wide range of NPs such as metals, (metal)oxides and quantum dots. The main 
benefits of ICP-MS over ICP-OES/AES is the higher sensitivity of ICP-MS (ppt range) compared to ICP-
OES/AES (ppm range) and that ICP-MS is capable of providing isotope information [28,29,61]. An 
important limitation of these techniques is that they do not allow quantification of NP uptake on a 
single cell level as the analysis is performed on the cell population as a whole. It is however possible to 
extrapolate this data to calculate the average NP uptake per cell after determination of the total 
number of cells per sample. Nevertheless, one must take into account that this average is expressed 
as the average mass of the element per cell instead of the average number of NPls per cell, although a 
conversion is possible if the mass and size of the NPls is known [29,85]. Modifications of ICP-MS have 
become available that allow single cell ICP-MS [86] or single particle ICP-MS [87]. In both cases, highly 
diluted samples are used so that each signal corresponds to a single particle or cell. Single particle ICP-
MS allows quantification of mass concentration, particle size and particle number in complex 
environmental and biological matrices, while single cell ICP-MS allows quantification of NPl content in 
individual cells [85,87,88]. A second issue that needs to be overcome is, similar to flow cytometry, the 
differentiation between cell-associated NPls and internalized NPls. As these methods are often used 
on metallic/metal oxide NPs, chemical etching is typically used as discussed above and schematically 
presented in Figure 2C [40]. As a possible alternative, Hou et al. described a rapid laser-based method 
to selectively desorb and ionize extracellular AuNPs [89]. 
Other techniques to study NP uptake – often less frequently used – include Raman spectroscopy and 
labeling of particles with radioisotopes. In Raman spectroscopy, a Raman fingerprint is obtained based 
on inelastic scattering of laser light due to the interaction of photons with molecular vibrations. 
Inelastic scattering of photons is a very inefficient process, but Raman band intensities can be 
enhanced several orders of magnitude by adsorbing a molecule on a metallic surface, typically 
composed of Au or Ag [90,91]. Surface enhanced Raman scattering (SERS) offers high sensitivity, 
minimal sample preparation and resistance to photobleaching and was successfully applied for the 
quantification of NPs uptake [92,93]. Huang et al. used SERS to investigate the cellular internalization 
of graphene oxide loaded with gold NPs. By combining SERS with light microscopy and TEM, they 
concluded that cell entry happened mainly via energy-dependent, clathrin-mediated endocytosis [94]. 
Furthermore, it should be mentioned that labeling of NPls with radioisotopes has also been used to 
quantify NPl uptake in cells. This approach allows quantitative evaluation with high sensitivity both in 
vitro and in vivo [95,96]. However, many drawbacks are related to working with radioisotopes such as 
difficult particle preparation and restricted use by regulations involving disposal of materials [28]. On 
a side note, it is worth mentioning that PCR is frequently used to quantify the amount of NA molecules 
delivered to the IC environment. Colombo et al. quantified intracellular siRNA concentrations using 
reverse transcription (RT) and stem–loop quantitative PCR after administration of siRNA-loaded lipid-
polymer hybrid NPls to H1299 cells that stably expressed eGFP [97]. The technique has a wide range 
of quantification but lysing cells, isolating and purifying DNA and running PCR is considered a time-
consuming process. However, some researchers state that it should be amenable to high-throughput 
formats and automation [19,20,98,99]. 
2.1.2. Elucidating cellular uptake pathways and intracellular trafficking 
NPls commonly find their way into cells through distinct endocytic pathways, as reviewed elsewhere 
[23–25]. A common methodology to find out which pathways are involved is via exclusion studies 
where pharmacological or biological agents that can shut down a particular pathway are used and any 
remaining NPl uptake is quantified. The decrease in NPl uptake relative to untreated cells is a measure 
for the importance of that particular pathway [25,100]. While any of the above mentioned techniques 
to measure NPl uptake can be used for this, in practice flow cytometry is used the most. A plethora of 
pharmacological inhibitors is available [23,101] and their use is quite widespread [100,102–104]. Yet, 
one should bear in mind that such inhibitor experiments should be interpreted with care. It has been 
shown that chemical inhibitors of endocytosis, such as chlorpromazine or genistein, show poor 
specificity and that their effect is highly cell line-dependent [104]. To avoid the problem of non-
specificity, biological strategies such as RNA interference or the introduction of dominant-negative 
mutants can be used to inhibit specific endocytic pathways [101,105,106]. The main drawback here is 
that these compounds could affect cell viability and are frequently observed to influence other 
endocytic pathways [101,104]. 
Fluorescence colocalization microscopy is another very popular technique to study not only 
internalization pathways but especially the subsequent intracellular trafficking of NPls. Here, 
colocalization analysis methods are applied to microscopy images of fluorescent NPls that may or may 
not coincide with fluorescently labeled subcellular structures or compounds [107–109]. Labeling of 
specific endocytic proteins is frequently performed either by immunostaining of fixed cells or, in live 
cells, by transfecting cells with fluorescent protein constructs (Figure 3A) [110]. Specific proteins 
related to uptake and trafficking include caveolin-1, flotillin-1, Rab5, Rab7 and LAMP-1, markers for 
caveolae-mediated endocytosis, flotillin-mediated endocytosis, early endosomes, late endosomes and 
lysosomes respectively. However, one should be mindful of potential artifacts due to protein 
overexpression, such as interactions that do not occur under normal circumstances due to low affinity, 
miscolocalization of the fusion protein or aggregation and fusion of organelles [100]. One notorious 
example is the mistaken discovery of the so-called “caveosome”, which was later declared to 
correspond to late endosomal compartments modified by the accumulation of overexpressed 
caveolin-1 awaiting degradation instead of a distinct endosomal compartment [111,112]. Apart from 
labeling specific proteins, a diverse array of organelle probes is available such as Lysotracker 
(lysosomes) or Mitotracker (mitochondria) that are designed to accumulate in specific IC structures 
(Figure 3B) [113,114]. Using Lysosensor yellow/blue, Wang et al. performed ratiometric imaging to 
study the effect of cell-penetrating peptides on the intracellular distribution of NPs in live cells. The 
Iblue/Igreen ratio of Lysosensor in every pixel was measured and assigned a pH value based on a 
calibration curve. These pH values were then categorized into endosomes (pH 5-6) or lysosomes (pH 
<5) and distribution of NPs in endolysosomal compartments was quantified by correlating the pH value 
with the fluorescence intensity of the NP at each pixel [115]. It should be noted however that 
combining acidotropic dyes (e.g. Lysotracker), which preferentially accumulate in acidic vesicles such 
as late endosomes and lysosomes, with proton sponge-based NPls could influence the outcome of 
colocalization assays. Since proton sponge-based NPls exert a buffering effect on endosomes, they 
could potentially inhibit staining with these acidotropic dyes. However, it is not clear if successful 
staining of endosomes in combination with proton sponge-based NPls indicate a lack of buffering effect 
since an increased flux of protons into the endosome would allow acidification and thus staining of the 
endosomes [116–118]. It is also possible to use fluorescently labeled ligands (e.g. LacCer, CTB and 
cholera toxin) with known internalization pathway (Figure 3C) [119]. Nevertheless, it should be noted 
that even though these markers may exploit distinct uptake mechanisms, further IC trafficking of these 
markers is rarely differentiated and they frequently end up colocalized [100]. In this regards they are 
more suited for studying internalization pathways rather than IC trafficking.  
 
Fig. 3 Evaluation of NPl colocalization with intracellular structures. (A) NPs are labeled in green and are incubated with the 
cells for 30 min or 4 h before staining of specific endocytic proteins using AF568-labeled antibodies (red). Antibodies were 
used to label the early endocytic marker EEA1 and the late endocytic marker Rab7. Scale bar represents 20 µm. Images 
adjusted from [120] with permission of The Royal Society of Chemistry. (B) NPs are labeled in green and are incubated with 
cells for 30 min or 24 h before staining the lysosomes with Lysotracker Red. Scale bar represents 20 µm. Images adjusted 
from [120] with permission of The Royal Society of Chemistry. (C) Upper images: cells were incubated for 4h with C6 labeled-
NPls (green) and AF594-Cholera toxin subunit B (CTB; red), a known endocytic marker of caveolae-mediated internalization. 
Lower images: cells are incubated for 4h with Cy5 labeled-NPls (red) and AF488-CTB (green). Scalebar represents 10 µm. 
Images adapted from [121]. © 2017 Public License (D) Spatiotemporal trafficking profile of p(CBA-ABOL) nanoplexes in ARPE-
19 cells. Graph shows the percentage of polyplexes that colocalize with late endosomal markers (LAMP1, Rab7, Golgi, Flotilin2 
and Rab11), obtained with the dynamic colocalization algorithm based on trajectories. Image reprinted with permission of 
[108]. © 2011 American Chemical Society. (E) Upper image: cell incubated with polystyrene NPs (red) and macropinosome-
labeling (green); imaged via conventional confocal microscopy. Lower image: same cell imaged via stochastic optical 
reconstruction microscopy (STORM), demonstrating the vast improvement in resolution over traditional confocal microscopy. 
Image size is 40 µm and inset size is 5 µm. image adapted with permission from [26]. © 2016 Americal Chemical Society. 
It is of note that some types of highly scattering or reflective NPs, such as AuNPs, can be visualized by 
microscopy in reflectance mode so that they do not have to be labeled with a fluorophore. This only 
works well using a microscope with optical sectioning ability, such as confocal microscopy or total 
internal reflection microscopy (TIRM). For instance, TIRM was used to study the colocalization of GFP-
clathrin with 500 nm colloidal particles. Unfortunately, since the penetration depth of the evanescent 
field is limited to approximately 200 nm, TIRM can only be used to study events close to the plasma 
membrane at the coverslip interface, i.e. the initial stages of NPl internalization [122]. For trafficking 
in live cells it is important to use a microscope that combines speed with sensitivity. For instance, a 
disadvantage of CLSM is the relatively low rate at which images can be recorded, especially when 
visualizing small and/or dim objects which need slow scan speeds to collect enough photons. A solution 
is provided by spinning disk confocal microscopy, where a disk with a series of pinhole apertures is 
used so that several pixels are illuminated simultaneously and light can be collected from all of them 
at the same time. In this way, fast confocal acquisition in live cells can be performed, albeit at a 
somewhat reduced confocality (i.e. lower contrast) due to pinhole crosstalk [123]. 
In static colocalization, the overlap of two objects is analyzed based on static images and color merges 
are frequently used to provide qualitative information (e.g. green + red = yellow). However, a proper 
understanding of these experiments requires quantitative analysis of colocalization. Strategies for 
static colocalization quantification can be categorized into object-based or pixel-based, the latter being 
subdivided into co-occurrence and correlation measures. In co-occurrence methods, the Manders 
coefficients are well-established and calculate the percentage of total signal from one channel that 
overlaps with signal from the other channel, based only on the presence or absence of signal. In 
correlation measures, the Pearson coefficient measures linear correlation, i.e. the extent of a 
relationship between signals in both channels [124–126]. Besides static colocalization, dynamic 
colocalization, where a colocalization algorithm looks for correlated movements of two objects, can 
be used as well. In dynamic colocalization, photobleaching is increased because of longer acquisition 
times but chances for false positives are highly reduced. Moreover, dynamic colocalization allows 
spatiotemporal characterization of NPl internalization. Vercauteren et al. first performed quantitative 
live-cell fluorescence microscopy to study the IC processing of poly(amido amine) poly(N,N0-
cystaminebisa- crylamide 4-aminobutanol) (p(CBA-ABOL)) NPls in retinal pigment epithelium (RPE) 
cells. They found that NPls were specifically delivered to Rab5- and flotillin-2-positive vesicles and were 
subsequently trafficked to Rab7 and LAMP-1-labeled endolysosomes, where the major fraction 
remained entrapped (Figure 3D) [108]. When objects are closer to one another than the optical 
resolution limit, they always appear to be colocalized in static microscopy images. This is resolved in 
dynamic colocalization experiments where it is the correlated motion of two objects (NPl and 
endosome) that is taken as a measure of true colocalization. While being more reliable, it is, however, 
more demanding in terms of experiments and analysis. Also super-resolution techniques are proving 
useful to enhance the reliability of colocalization experiments. Shang et al. prepared NPs for super-
resolution imaging and imaged their internalization in living cells with STED nanoscopy [102]. Van der 
Zwaag et al. evaluated colocalization of 80 nm PS NPs with the plasma membrane, macropinosomes 
(Figure 3E), nuclear membrane and actin using STORM, thereby allowing to resolve subdiffraction 
endocytic vesicles [26]. Li and coworkers used dynamic colocalization via PALM to visualize clathrin-
dependent internalization of polystyrene NPs with different sizes by COS-7 cells [127]. However, the 
true competence of super-resolution microscopy in the intracellular trafficking of NPls remains to be 
demonstrated. 
Due to the limitations associated with both exclusion and colocalization assays, it is worth mentioning 
that these assays are often performed simultaneously to confirm or further investigate observations. 
A nice example is provided by Sahay et al. who identified the internalization pathway required for 
cationic siRNA-containing lipid nanoparticle (LNP) entry into HeLa cells. Downregulation of Cdc42 and 
Rac1 (regulators of macropinocytosis) led to an 80% decrease in uptake, whereas inhibition of caveolin-
1 and clathrin heavy chain-1 (regulators of caveolae- and clathrin-mediated endocytosis respectively) 
had little impact on LNP internalization. Cellular entry through macropinocytosis was then further 
confirmed through strong colocalization with Cdc42-GFP and ovalbumin-positive vesicles (both 
markers for macropinocytosis) [17]. Another example is supplied by Zhou et al. who studied the 
influence of  oligoarginine modifications on the internalization of polymeric NPs. The authors 
performed flow cytometry experiments after treatment with chemical endocytic inhibitors, 
colocalization assays using immunostaining of specific endocytic proteins (e.g. Rab 7) and 
colocalization with organelle-specific fluorescent markers (e.g. Lysotracker) [120]. 
Another method to study the distribution of NPls in endocytic vesicles is subcellular fractionation, 
where organelles such as early endosomes, late endosomes and lysosomes are separated through 
density-gradient centrifugation [128,129]. Although fractionation allows evaluation of a large number 
of cells, the method has proven to be experimentally challenging. The main drawbacks are the difficulty 
of identifying endocytic vesicles after centrifugation since they have many marker proteins in common 
and do not vary greatly in density. Furthermore, the requirement of breaking the cells before 
separating the intact organelles can induce damage or rupture of internal vesicles. Therefore, Lazebnik 
and coworkers developed an approach based on the polymerization of 3,3’-diaminobenzidine (DAB), 
a membrane-permeable molecule, by endocytosed horseradish peroxidase (HRP), a marker for fluid 
phase pinocytosis, in the presence of H2O2. In this way, only vesicles containing HRP were crosslinked, 
wich increased the vesicles’ density and made the vesicles resistant to detergents. As a consequence, 
insoluble crosslinked vesicles (early endosomes, late endosomes or lysosomes – determined by 
localization and thus incubation time of HRP) were easily separated from non-crosslinked vesicles using 
a detergent. Next, the relative fractions of PEI/AF647-siRNA NPls in early endosomes, late endosomes 
and lysosomes were quantified by measuring the fluorescence of the supernatant and comparing it to 
the fluorescence of the supernatant of matching samples where H2O2 was omitted and thus 
crosslinking was inhibited [27]. Alternatively, Bertoli and coworkers used the magnetic properties of 
NPs to isolate NP-containing endosomes from A549 cells at different times. Recovered fractions were 
tested against different markers of the endolysosomal pathway by Western Blot to evaluate the 
distribution of NPs [130]. 
Although used less frequently, analytical methods can be employed to study NPl endocytosis, provided 
that the NPl meets the rather specific requirements related to the selected method such as magnetic 
properties or absorbing of the material to a metallic surface for SERS applications. In 2014, Hofmann 
et al. introduced a mass spectrometry method to study IC trafficking. IC vesicles containing 
superparamagnetic iron oxide polystyrene NPs (SPIOPSN) were magnetically isolated and their protein 
composition was analyzed by label-free quantitative MS. Proteomics identified relevant proteins 
involved in a macropinocytic-like internalization pathway, guiding the NPs via macropinosome-like 
vesicles towards the final destination inside multilamellar lysosomes [131]. Huefner et al. successfully 
applied a reporter-free SERS method to generate a color-coded distribution of PCA-LDA (principal 
component analysis – linear discriminant analysis) derived spectral features in SERS maps of cells, 
allowing detailed hyperspectral characterization of endosomes and lysosomes in SH-SY5Y human 
neuroblastoma cells. Furthermore, this method allowed determination of vesicular localization of 
AuNPs and revealed the molecular environment throughout the cellular uptake pathway [132]. 
2.2. Exocytosis 
Cells use the process of exocytosis to remove membrane proteins such as transporters and ion 
channels, to excrete essential molecules, to communicate with other cells or to repair the plasma 
membrane [133]. However, this natural cellular process can interfere with the delivery of NPls for gene 
therapy. During endocytic confinement, NPls can be exocytosed via three different routes. First, early 
endosomes can fuse with recycling endosomes that direct the cargo towards the plasma membrane 
for recycling. Second, following early endosome maturation into late endosomes, multivesicular bodies 
(MVBs) can arise that fuse with the plasma membrane, thereby releasing their content outside the cell, 
for instance in the form of exosomes. Contrary to the lumen of these MVBs that can inherit NPls from             
late endosomes, exosomes can contain NPls only when MVBs pick them up from the cytoplasm after 
successful endosomal escape upon formation of the exosomes. A similar type of extracellular vesicles, 
named ectosomes, originate directly from budding at the plasma membrane and could also contain 
NPls, picked up from the cytoplasm, if endosomal escape was realized [22,134–136]. Thirdly, the ER-
Golgi secretory pathway, active after intracellular sorting of the NPl cargo, is defined as “conventional 
exocytosis” [22]. In contrast to the extensive study of cellular uptake mechanisms of NPls in the last 
decades, little is known to date about NPl excretion from cells. Understanding the involvement of 
exocytosis is relevant because exocytosis of NPls may cause a change in protein corona, leading to 
unwanted toxicity or unpredicted biological effects [133]. Additionally and most importantly, efficiency 
of gene delivery is effectively reduced when NPls are directed back out of the cells [17,133,137]. 
The most straightforward method to quantify exocytosis of NPls is to measure the amount of expelled 
NPs in fresh medium or the decrease of internalized NPs in function of time. One way to do this is by 
measuring the fluorescence of labeled NPls [17]. Shukla et al. estimated exocytosis of AF647-labeled 
siRNA from HSC-T6 cells by evaluating the fluorescence in freshly added medium after several time 
points [138]. Alternatively, Yanes et al. measured the decrease in IC fluorescence after administration 
of FITC-labeled mesoporous silica-based nanomedicines to A549 cells as an indication of the amount 
of exocytosis [139]. Likewise, Jiang et al. studied exocytosis of QDs using spinning disk confocal 
microscopy to calculate the fraction of exocytosed QDs based on the decrease in IC fluorescence after 
applying fresh cell medium [60]. However, it should be noted that evaluating exocytosis based on a 
decrease in IC fluorescence is tricky since there are other mechanism that can lower IC fluorescence 
(e.g. degradation). When working with AuNPs, fluorescent measurements can be replaced by dark-
field microscopy to estimate exocytosis as AuNPs are strong light scatterers [140]. Alternatively, ICP-
coupled spectrometry methods can be used for quantitative assessment of exocytosis of metallic and 
inorganic NPs [141,142]. Strobel et al. used ICP-MS to measure the concentration of Ce (related to 
amount of CeO2 NPs) in cell culture medium supernatants of HMEC-1 cells with or without the addition 
of exocytosis inhibitors [143]. However, with this approach it is not possible to differentiate between 
intact NPls and their breakdown products [133,144]. 
Fluorescence microscopy can be used as well to study NPl exocytosis. Besides live-cell imaging to 
observe exocytosis in real-time [145], colocalization with relevant subcellular structures is frequently 
used as well. To evaluate exocytosis in the form of exosomes, colocalization with CD9, an established 
protein marker of exosomes, can be studied [105]. However, the most studied protein involved in 
endocytic recycling is Rab11, a protein that is primarily associated with recycling endosomes and 
regulates recycling of endocytosed material [146,147]. An example is again provided by Sahay et al., 
who found that LNP showed colocalization with Rab11-positive recycling endosomes, labeled via 
Rab11-antibodies or by transfection with Rab11-GFP pDNA. Surprisingly, however, Rab11 depletion 
did not improve LNP retention. Depletion of Rab8a (which blocks secretion from the Golgi/ER after 
material exchange with late endosomes) and Rab27b (which blocks exosome secretion and/or fusion 
with the plasma membrane) did increase LNP retention, leading to enhanced silencing. This phenotype 
of increased retention was also observed when LNPs were applied to mouse embryonic fibroblasts 
devoid of Niemann Pick type C1 (NPC1). NPC1 is a 13 transmembrane glycoprotein that is located on 
the surface of late endosomes. Subcellular trafficking of lipids from late endosomes and lysosomes 
towards the EC environment has been reported to utilize NPC1 and the absence of this protein causes 
late endosomal and lysosomal dysfunction. Combining all this information led the authors to conclude 
that LNPs are exocytosed through NPC1-mediated recycling, independent of Rab11 function. This 
result was consistent with previous reports that indicated that NPC1-mediated recycling was 
independent of Rab11 function even though some colocalization with Rab11-positive vesicles was 
shown [17]. Besides colocalization assays, single particle tracking (SPT) can be used to study exocytosis. 
Jin et al. used SPT to study the movement of single-walled carbon nanotubes as they were expelled 
from NIH-3T3 cells. Comparable to dynamic colocalization, photobleaching is the major limitation for 
SPT measurements, since the photobleaching time constrains the total observation time [148]. 
2.3. Endosomal escape 
Cellular uptake through the process of endocytosis results in the cargo residing in endosomes, thus 
being physically separated from the cytoplasm by the endosomal limiting membrane. Escape out of 
the endosomes is generally required since endosomal sequestration potentially causes enzymatic 
degradation in lysosomes, recycling out of the cell or may prevent the particle or its therapeutic cargo 
from reaching the intended intracellular target. NPls are, therefore, often designed to have some form 
of endosomal escape mechanism [13,116,149]. Several approaches have been developed to promote 
endosomal escape of NPls including the use of cell penetrating peptides, the flip-flop phenomenon, 
the proton sponge mechanism, pore formation and membrane fusion. A detailed description of these 
mechanisms has been subject of numerous reviews [150,151]. However, despite extensive research 
performed in the last decades, endosomal escape remains a highly inefficient process as, typically, less 
than 10% of NPl-containing vesicles show efficient endosomal release [152]. Even though it has been 
proven difficult, quantifying endosomal escape efficiency and elucidating release mechanisms of NPls 
could improve our understanding of this formidable IC barrier, which in turn may lead to the design of 
new and improved NPls [153]. Besides quantification, qualitative information about the mechanism of 
endosomal escape can be useful since enhancing endosomal escape efficiency requires prior 
knowledge about the mechanism of endosomal release. Therefore several assays that provide 
information about endosomal escape mechanisms are available, as discussed in more detail in a recent 
review by our group [116]. 
In the context of NA delivery, endosomal escape efficiency is often related to the extent of reporter 
protein expression as a consequence of mRNA and pDNA translation or silencing of the reporter 
protein expression by siRNA [116,154,155]. Although endosomal escape is related to the final level of 
protein expression, one should be careful interpreting these results since several other barriers could 
influence the therapeutic effect of NAs after successful endosomal escape. As such there is a need for 
more specific assays to quantify endosomal escape specifically without the influence of subsequent 
barriers. 
The most well-established method to evaluate endosomal escape efficiency is via fluorescence 
microscopy. The transition from a punctate (endosomal confinement) to a diffuse (cytosolic release) 
intracellular fluorescence pattern (IFP) is frequently used as a qualitative confirmation of endosomal 
escape [116]. Since out of focus light can falsely give the impression of diffuse staining, confocal 
microscopy is recommended to evaluate the IFP [116,153]. A first way to do this is by co-incubation 
with small fluorescent molecules such as labeled dextrans or calcein, as shown in Figure 4A [156–159]. 
Calcein has the specific advantage that it can be loaded in self-quenching concentrations, making the 
diffuse cytoplasmic staining brighter due to dequenching of the fluorescence upon dilution of calcein 
into the cytoplasm. However, one should remain cautious when drawing conclusions from these 
experiments, since the release of a small molecule such as calcein doesn’t necessarily guarantee the 
release of the cargo of interest. Calcein release can be evaluated after co-incubation with a wide array 
of NPls but also after incorporation into the lumen of liposomes. When present in the liposomal lumen, 
calcein will reach the cytosol due to fusion of liposomes with the endosomal membrane, as membrane 
fusion is the preferential mechanism of endosomal release for liposomes [160,161]. Loading calcein 
inside the liposome has the benefit of visualizing the NPl itself and avoiding interactions between the 
NPl and the co-incubation solution. A related methodology to determine the endosomal escape 
capacity of a variety of NPls was provided by Rehman et al. who co-incorporated a high concentration 
of fluorescently labeled oligonucleotides (ONs) in NPls. When the NPl resides in the endosome, the ON 
fluorescence is mostly quenched. Upon endosomal escape, the labeled ONs are released, resulting in 
a local burst of fluorescence due to dequenching and eventual accumulation into the nucleus, as 
illustrated in Figure 4B. With this method it is not only possible to count the number of endosomal 
escape events within a cell, it also allows to visualize endosomal escape in real-time, pinpointing 
endosomal escape events in time and place. Additionally, by evaluating the rate of ON accumulation 
into the nucleus, the authors showed that the polymeric carrier PEI induces a sudden burst (proton-
sponge effect) whereas a more gradual leaking occurred with a lipid based carrier [162]. The transition 
of a punctate to a diffuse pattern to evaluate endosomal escape can also be used if the cargo itself is 
labeled. Clearly, this would only work for cargo that is small enough (e.g. siRNA) to diffuse through the 
cytoplasm upon endosomal release. Basha et al. used this strategy to examine the effect of different 
lipids on the cytoplasmic delivery of cy5-labeled siRNA [163]. However, the dose needed to visualize 
cytosolic siRNA with most microscopes is far above the therapeutic range [164]. To extend the dynamic 
range, Wittrup et al. used a spinning disk microscope with two different exposure settings. Most of the 
cellular volume was imaged with short exposure times so as to visualize the brightest structures within 
the cells (e.g. intact lipoplexes and vesicles). Next, they focused on a particular plane in the cells and 
recorded an image with a long exposure time, intentionally overexposing bright areas to detect weakly 
fluorescent siRNA signal in the cytosol. Using this method, they could observe the sudden cytosolic 
release of AF647-siRNA from lipoplex-containing vesicles in HeLa cells, as depicted in Figure 4C. 
Furthermore, they found that galectin-8 recruitment can be used to identify the siRNA-releasing 
endosomes as it recruits to the damaged endosome within 5-10 s after cytosolic siRNA detection [152]. 
 
Figure 4 Microscopic evaluation of endosomal escape. (A) Visualization of calcein uptake and release after co-incubation 
with AuNPs conjugated to cell-penetrating peptides for 4h. Left: the cell in the dotted box shows a clear punctate intracellular 
fluorescence pattern (IFP) due to endosomal uptake of calcein. Right: calcein has spread as a diffuse staining towards the 
entire cytoplasm, indicative of endosomal escape. Scalebars represent 20 µm. Images adapted [159]. © 2016 Public License. 
(B) Upon endocytosis of the NPl with co-incorporated FITC-labeled ONs, the fluorescence of these ONs is efficiently quenched. 
The NPl can be seen as a fluorescent dot (white arrow in frame 1). Upon endosomal escape, the fluorescence of these ONs is 
dequenched (frame 2) and spreads throughout the entire cytoplasm (frame 3). Eventually, FITC-ONs will readily accumulate 
inside the nucleus (frame 4). Images reprinted with permission of [162]. © 2013 American Chemical Society (C) Left: protocol 
used by Wittrup et al. to visualize sudden cytosolic release of AF647-siRNA. Short exposure times, adjusted to the brightest 
structures in the cell, were used to image the cell at several z-positions (grey lines). Next, a single plane was captured with 
longer exposure time to detect the weakly fluorescent siRNA signal in the cytosol. Right: single-plane images at long exposure 
times reveal that the released siRNA rapidly diffuses throughout the entire cytoplasm upon endosomal escape. Scale bar 
represents 10 µm. Images reprinted with permission from Springer Nature Nature Biotechnology [152] © 2015. 
In order to distinguish cytosolic NPls from those still sequestered in endolysosomal compartments, 
colocalization analysis can be employed. When NPls are situated in the cytoplasm, they are no longer 
colocalized with endosomes. Therefore, the lack of colocalization with endosomal compartments is an 
indirect measure for endosomal escape [110,165–167]. Of course this method essentially relies on 
being able to see all types of endosomes. Non-specific endosomal markers such as dextrans or 
transferrins or markers that will end up in most endocytic vesicles like plasma-membrane specific dyes 
are best suited for this. 
Changes in the microenvironment of the NPl can also be useful to evaluate endosomal escape 
efficiency. For instance, Deng et al. developed a ratiometric pH-sensing nanoprobe that was used for 
quantitative, high-throughput evaluation of endosomal escape. The nanoprobes were co-incubated 
with several polymeric NPls in order to examine endosomal escape efficiency of the NPls. This 
intracellular pH-sensing probe is able to estimate the efficacy of endosomal escape since it senses a 
change in pH when going from the acidic endosomal environment to the cytosol, thereby altering its 
fluorescence [168]. Alternatively, Wang et al. designed a quantitative redox-activatable sensor (qRAS) 
for the real-time monitoring of cytosolic delivery of macromolecules, again via co-incubation. The 
qRAS-labeled macromolecules are silent inside the endosomal compartment but are switched on by 
redox activation upon delivery into the cytosol after endosomal escape [169]. The main benefit of 
these methods lies within the fact that they can be used as a high-throughput technique to evaluate 
endosomal escape. However, the use of high-throughput measurements does not allow for direct 
visualization of the processes, in contrast to confocal microscopy, a largely qualitative and low-
throughput technique [168,169]. 
Due to its unparalleled resolution, electron microscopy (EM) allows to visually distinguish between 
NPls that are sequestered in endolysosomal vesicles or located freely in the cytoplasm [110,165,170]. 
However, excessive sample preparation and complex image analysis limit the amount of cells that can 
be evaluated, thereby making it difficult to extract quantitative information. Furthermore, fixation 
artefacts can make visual assessment of endosomal escape challenging [116]. Gilleron et al. developed 
a semi-automatic quantification of EM images where automatic detection of LNP-siRNA-gold NPs was 
followed by manually assigning the particles to either endosomal compartments or the cytoplasm in 
order to quantify endosomal escape. This way, they estimated that siRNA escape from endosomes into 
the cytosol occurred at low efficiency and during a limited window of time [164]. 
Subcellular fractionation can be used as well to physically separate endosomal vesicles from the 
cytosol. The amount of NP or cargo present in the vesicle or cytosol fractions can then be measured 
by classic analytical techniques, such as PCR [171,172] and fluorimetry [129]. However, considering the 
uncertainty of perfect separation of both fractions it is advised to seek further confirmation with other 
assays [116,171]. Finally, two additional tests are discussed with the sole aim to obtain more 
information on the mechanism of endosomal escape. In order to examine the influence of pH on 
endosomal escape, the pH-responsiveness of the NPl or the pH of the endosomal compartment itself 
could be altered. To this end, V-type proton-pump ATPase inhibitors such as bafilomycins or 
concanamycins are frequently used since they block the acidification process altogether [173]. The 
difference in endosomal escape between the normal scenario and the pH-adjusted scenario is then 
evaluated using the different assays discussed above. The use of buffering agents such as chloroquine, 
monensin or ammonium chloride is not recommended since they might enhance endosomal escape 
due to the proton sponge effect rather than block it [116]. Finally, to study endosomal escape via 
membrane fusion, the fusion of lipids is usually assayed by dye dilution. A frequently used technique 
in this regard is Förster resonance energy transfer (FRET) where fluorescent markers consisting of a 
donor and acceptor pair are present on the vesicle surface. Upon membrane fusion, they are diluted 
over the increased surface area so that FRET efficiency goes down.[174] Dilution can then be 
monitored via spectrofluorimetry or fluorescence microscopy. The major limitation of this assay is that 
it cannot distinguish between lipid fusion and lipid mixing, which is important since lipid mixing does 
not result in cytosolic release of the therapeutic cargo. To this end, a fluorescent content marker can 
be incorporated into the NPl since the loss of its fluorescence will indicate fusion instead of mixing 
[116]. 
2.4. Autophagy 
Distinct from the endocytic pathway, autophagy is mediated by autophagosomes that have engulfed 
a portion of the cytoplasm for non-selective degradation. As depicted in Figure 1, during the process 
of autophagy a phagophore is created and evolves into a double-membraned autophagosome upon 
sequestration of cytoplasmic material. Next, this autophagosome can fuse with a lysosome, generating 
an autophagolysosome in a process typically referred to as “autophagy flux”. Alternatively, an 
amphisome can be created when an autophagosome merges with an endosome [175]. Autophagy is 
an evolutionary conserved process that supports cell preservation through degradation of cytosolic 
material. Recently, it has been discovered that autophagy has a greater variety of physiological roles 
than initially expected including cell cycle regulation, tumor suppression, development, anti-aging, etc. 
However, autophagy poses an additional barrier to efficient gene delivery since it can recapture NPls 
after their initial escape to the cytoplasm and can redirect them towards lysosomal degradation 
[22,176,177]. Roberts et al. reported that inhibition of autophagy by knockdown of Atg5 (autophagy-
related protein 5) led to an 8-fold increase in gene expression efficiency, thereby confirming that 
autophagy can act as a substantial barrier in gene therapy [178]. In order to examine the extent of 
autophagic activity for a particular NPl and cell type combination, a variety of established methods are 
already available. In 2016, Klionsky et al. published the third version of a guideline paper to standardize 
the use and interpretation of autophagy assays [179,180]. 
TEM was the first method used to evaluate autophagy and still remains important today as it provides 
highly detailed information. Assuming sufficient expertise, TEM allows detection of the distinct steps 
of autophagy since autophagy organelles show a specific morphology [181,182]. Duan et al. used 
ultrastructural analysis on TEM images, which indicated that SiO2 NPs induced autophagy in primary 
human umbilical vein endothelial cells (HUVECs), as shown in Figure 5A-H [183]. Likewise, Lopes et al. 
found a dose-dependent increase in the autophagic effect of TiO2 NPs on human keratinocytes 
(HaCaTs) [184]. Furthermore, recent technology breakthroughs in methods used to characterize 
cellular ultrastructure such as cryo-EM and Focused Ion Beam Scanning Electron Microscopy (FIB-SEM), 
have only just begun to contribute to autophagy research but promise to increase our understanding 
of autophagy processes [185]. 
 
Figure 5 Evaluation of NP-induced autophagy via TEM. (A-B) Untreated human umbilical vein endothelial cells (HUVECs) with 
normally shaped organelles. (C-D) HUVECs treated with SiO2 NPs show cytoplasmic vacuoles that contain electron-dense NPs 
(white arrows). (E) Double-membraned phagophores evolving into autophagosomes (white arrows). (F) Autophagosomes 
(white arrows). (G) Autolyosomes/amphisomes containing cytoplasmic material (white arrows). (H) Autolysosomes/ 
amphisomes containing mitochondria and SiO2 NPs (white arrows). Image reprinted with permission from [183]. 
Using fluorescence microscopy, autophagy is often evaluated by quantifying the number of 
autophagy-related vesicles. This can be performed using the autophagic dye monodansylcadaverine, 
which selectively accumulates in autophagic vacuoles presumably because of ion-trapping and/or 
interaction with membrane lipids [186,187]. However, the specificity of this dye remains a matter of 
debate. Therefore, the more specific microtubule-associated protein 1A/1B light chain 3 (LC3), a major 
structural protein of autophagosomes, is the most frequently used marker for autophagy. Under 
normal conditions, cells transfected with a GFP-LC3-encoding construct exhibit a diffuse fluorescence 
spread throughout the cytoplasm. However, when the number of autophagosomes increases, they can 
be identified as distinct puncta [175,181,188]. Alternatively, colocalization assays of NPls with 
autophagy markers such as LC3 are frequently used to evaluate the role of autophagy in NPl-mediated 
gene delivery [17]. However, upon fusion with lysosomes, the autophagosomal membrane is degraded 
and LC3 expression is lost. Furthermore, LC3 has been observed on other vesicles such as phagosomes 
and macropinosomes, so it is advised to remain cautious when interpreting results [108,175,177]. It 
must be noted however that above-mentioned assays do not allow differentiation between 
upregulation of autophagy or an impaired clearance of autophagosomes (inhibition of autophagic 
flux), since they both result in an increased number of autophagosomes [175]. Co-treatment with 
lysosomal inhibitors to block lysosomal degradation can be used as an additional test to differentiate 
between an inhibited autophagic flux or a general induction of autophagy [180]. The distribution of 
several other proteins related to autophagy, such as p62 (also called sequestosome 1 or SQSTM1), can 
be evaluated as well. However, the validity of p62 as a marker for autophagy is being questioned since 
p62 is also involved in other cellular processes [178,186,189]. 
Alternatively, Western blotting can be used to evaluate autophagy flux or signaling events involved in 
autophagy. An impaired autophagy flux can be detected by evaluating the ratio of LC3-II/LC3-I 
(membrane-bound/cytosolic form of LC3) in the presence of lysosomal protease inhibitors (e.g. 
pepstatin A) or buffers (e.g. chloroquine) that inhibit LC3-II degradation. When LC3-II remains constant 
in the presence or absence of the inhibitor, autophagy flux is likely to be blocked. GFP-LC3 cleavage 
can also be determined by Western Blotting in order to evaluate autophagy flux. Since GFP is resistant 
to lysosomal hydrolysis, the amount of free GFP is correlated to autophagosome degradation. 
Additionally, an increase in undegraded p62 can indicate an autophagy flux blockage. Also actively 
studied is the activity of the mammalian target of rapamycin (mTOR) and its interacting proteins via 
Western Blotting by means of phospho-specific antibodies [175,181,190]. Song et al. postulated that 
it is important to assess involvement of mTOR-dependent autophagy in NP degradation since they 
described distinct results for mTOR-dependent and mTOR-independent autophagy regulators. For 
instance, induction of mTOR-dependent autophagy by rapamycin increased siRNA knockdown 
whereas induction of mTOR-independent autophagy by LiBr diminished siRNA silencing tremendously 
[191]. 
Finally, enzyme-linked immunosorbent assay (ELISA) can be used to evaluate autophagy and several 
kits are already available on the market (e.g. p62, Atg5). These assays allow high-throughput 
quantification of autophagic activity [192,193]. Recently, Oh et al. reported on an assay to evaluate 
autophagy flux using ELISA with two LC3 antibodies. Using this technique, changes in membrane-
associated LC3-II levels and the ratio of LC3-II to LC3-I levels were evaluated. The authors demonstrated 
that this ELISA technique was more sensitive and reliable for the detection of a blocked autophagy flux 
compared to the most commonly used LC3 turnover assay via Western blot. However, since ELISA is 
unable to quantify LC3-I and LC3-II levels simultaneously in a single well, detection should be preceded 
by separation of subcellular compartments [189]. 
It should be noted that in order to draw correct conclusions it is advised to combine several techniques 
to evaluate autophagy. Song et al. evaluated the role of autophagy after administration of 
lipofectamine 2000 or chitosan NPls in H1299 cells by showing an increased number of MDC-stained 
vesicles, a significant increase in LC3-II expression via Western Blotting and colocalization of siRNA with 
LC3-labeled autophagosomes [191]. Another example is provided by Zhong et al. who evaluated 
autophagy in mouse fibroblasts after transfection with PEI/DNA polyplexes. Polyplex-induced 
autophagy was confirmed by visualization of autophagosomes via TEM, light microscopic detection of 
IC LC3-aggregation into distinctive puncta and elevated expression of LC3-II protein, measured by 
Western Blotting [194]. 
2.5. Vector unpacking 
Another issue that should be considered is the kinetics of cargo release from the carrier. The stability 
of the interaction between carrier and cargo must be optimized since both premature dissociation and 
overly stable binding can be disadvantageous to the overall transfection efficiency. On the one hand, 
the vector needs to protect the cargo from enzymatic degradation through efficient complexation. On 
the other hand, the cargo needs to be dissociated from the vector prior to interaction with the final IC 
target (e.g. RISC complex for siRNA, translation machinery for mRNA and transcription machinery for 
pDNA) [12,18,195]. It has been stated before that there might be a difference in the best unpacking 
moment between lipoplexes and polyplexes. This is based on the observation that nuclear 
microinjection of liposome-pDNA complexes inhibited gene expression while PEI polyplexes did not. 
This suggests that polymers may still dissociate from the cargo inside the nucleus while lipid carriers 
should dissociate from their cargo before entering the nucleus [196,197]. Modulation of vector 
unpacking properties can be achieved by changing its chemical features, using stimuli-responsive 
strategies or by inclusion of enzymes, proteins or chemicals [198]. 
In order to study cargo association with or dissociation from a certain vector, gel electrophoresis is 
frequently used. When dissociation has happened, the cargo is free to migrate through the gel and 
form a detectable band. However, while this method allows to study vector unpacking under 
controlled lab conditions (e.g. in buffers with different pH), it cannot be used to study the stability of 
complexes in the actual cellular environment [199]. This is again where fluorescence microscopy 
comes in. In order to examine vector unpacking, the fluorescence intensity of the DNA intercalating 
dye YOYO-1 can be evaluated. When YOYO-1 labeled pDNA is complexed to the carrier, its fluorescence 
is decreased because of self-quenching. Consequently, when pDNA is released, the YOYO-1 signal 
increases substantially, which can be visualized in cells with fluorescence microscopy (or alternatively 
by flow cytometry) [200]. Another approach is based on colocalization of cargo and carrier, each 
labeled with a different fluorophore [198]. Using this method, Schaffer et al. demonstrated that vector 
unpacking can indeed be a limiting step for gene expression in large polymer constructs [201]. 
However, since components must diffuse far away from each other (further than the microscope’s 
resolution) to be detected as separate, colocalization methods do not provide sufficient sensitivity to 
detect the onset of dissociation. Förster resonance energy transfer (FRET) imaging may be used 
instead, which probes interactions on the sub 10 nm length scale. When the NPl is intact there will be 
high FRET efficiency, which reduces upon vector unpacking [198,202]. One should however be careful 
when using traditional organic fluorophores since they are susceptible to photobleaching and spectral 
cross-talk due to broad emission bands. A proposed solution is the use of quantum dots (QDs) as 
efficient FRET-donors since they have a broad absorption, narrow emission spectrum and are highly 
photostable [195,198,203]. Ho et al. used QD-mediated FRET to study the distribution and unpacking 
of individual chitosan NPls within HEK293 cells. The use of QD-FRET permitted an immediate detection 
of changes in the nanocomplex state intracellularly [195]. Another fluorescence based technique to 
study unpacking of complexes is dual color fluorescence fluctuation spectroscopy (dual color FFS). 
Here, fluctuations in fluorescence intensities are measured that originate from molecules that move 
in and out of a confocal detection volume. When cargo and carrier are associated, each labeled with 
its own fluorophore, the fluorescently labeled molecules move simultaneously, causing similar 
fluorescence time traces in both spectral channels. When dissociated, the molecules will move 
independently, resulting in a loss of similarity between both signals [198]. Lucas et al. successfully used 
dual color FFS on rhodamine green-labeled oligonucleotides complexed with Cy5-labeled polymers in 
order to characterize IC vector unpacking in Vero cells. On the downside, it should be noted that the 
number of particles that can be analyzed is limited since the detection volume is very small 
(femtoliters) and particles are highly diluted in the cytosol [204]. 
Magnetic resonance imaging (MRI) was also reported for the evaluation of vector unpacking. Park et 
al. conjugated ultrasmall superparamagnetic iron oxide (USPIO) to PEI polymers. This conjugate was 
capable of complexing pDNA and the T2 relaxation time of water enhanced by USPIO was shown to be 
a function of the packaging state of the vector. This technique can be used to study vector unpacking 
in in vivo situations since USPIO NPs itself are used as a contrast agents for MRI imaging with high 
resolution. Furthermore, NPl unpacking is studied while avoiding fluorescent labeling of NPls, thereby 
eliminating the issue of in vivo tissue autofluorescence and the issue of possible alteration of vector 
unpacking of unlabeled NPls vs fluorescently labeled NPls [205]. 
2.6. Cytoplasmic degradation 
Following successful endosomal escape and vector unpacking another significant barrier to gene 
delivery arises: nucleases present in the cytoplasm can degrade released NAs. For instance, several 
studies have demonstrated that the half-life of pDNA in the cytoplasm is in the range of 50-90 min 
[2,5,177]. Surprisingly, research on NA degradation in the cytosol remains rather limited to date, 
presumably because only few techniques are available to investigate this experimentally. 
In order to investigate the integrity of NAs, gel electrophoresis can be used [206]. However, specificity 
of this technique is limited to lab conditions since free NAs and other biomolecules will generate a high 
background in complex biologic environments. Alternatively, PCR can be used to investigate NAs 
because of the method’s high specificity and sensitivity. Recent advances in quantitative PCR have 
made measurements in undiluted biological samples possible by using a PCR buffer with a higher pH, 
eliminating the need for DNA isolation [207]. However, besides detecting intact plasmids, PCR also 
quantifies partially degraded plasmids that contain the amplified region, which is of course undesirable 
when evaluating NA degradation. A more suitable method to evaluate degradation would be Southern 
Blotting, where only intact plasmids are detected and quantified, as was performed by Vitiello et al. 
[208,209]. 
The above mentioned methods in any case do not allow to study NA degradation in real-time within 
the cell. An advanced fluorescence microscopy method in this regard is fluorescence correlation 
spectroscopy (FCS). From the fluctuations measured by this technique, arising from labeled NAs 
moving through the confocal detection volume, the diffusion coefficient of those molecules in the cell 
can be obtained from fitting a theoretical model to the experimental autocorrelation function. Using 
FCS, degradation can be monitored by an increase in diffusional rate of the NA [210]. Sasaki and Kinjo 
monitored the size and structure of double-labeled DNA by FCS and fluorescence cross-correlation 
spectroscopy (FCCS) after introduction of the DNA into the cytoplasm of COS7 cells by bead-loading. 
In FCCS, the fluorescence fluctuation patterns of the two labels are recorded and cross-correlated in 
order to evaluate if the two labels move simultaneously or not. The authors employed FCS to evaluate 
the diffusion properties of pDNA and FCCS to monitor the degradation of pDNA at the single molecule 
level [211]. As FCS and FCCS only obtain information from within a single focal point, Sasaki et al. also 
used cross-correlation raster image correlation spectroscopy (ccRICS) to visualize the spatial 
distribution of nuclease degradation in live cells. ccRICS was employed to visualize when and where 
exogenous DNA, injected into the cytosol, is degraded. Their results indicated that nuclease activity in 
the cytoplasm differs between cell lines, leading to the proposition that nuclease activity impacts the 
cell’s resistance to exogenous DNA incorporation [212]. More accessible than FCS or RICS is confocal 
FRET imaging, which can be used to determine NA degradation in the cytosol. In this case the NA should 
be labeled with strategically placed FRET pairs. Upon NA degradation, the FRET pair will dissociate, 
resulting in lower FRET intensities [110,213,214]. Chen et al. developed a two-step QD-FRET approach 
to monitor vector unpacking and cytoplasmic degradation at the same time. pDNA, double-labeled 
with QD and a NA dye was complexed with Cy5-labeled polymer. The QD donor drives energy transfer 
through the intermediate NA dye to the Cy5-labeled polymer. This way, three states of DNA 
condensation and integrity could be distinguished (complexed and intact, unpacked and intact, 
unpacked and degraded) [215]. Remaut et al. used FRET-FCS to study the IC degradation of single-
stranded oligonucleotides (ONs). ONs were labeled on the 3’ end with rhodamine green and on the 5’ 
end with Cy5, resulting in high FRET efficiency as long as the ONs are intact and loss of FRET signal 
when the ON are degraded [216]. Finally, Lechardeur et al. used fluorescence in situ hybridization 
(FISH) in combination with quantitative single-cell fluorescence video-image analysis to determine for 
the first time the half-life of single- and double-stranded circular pDNA delivered by microinjection in 
HeLa and COS cells [217]. 
2.7. Nuclear entry 
Nuclear entry is the final barrier that needs to be overcome for successful pDNA delivery [218]. The 
nuclear envelope consists of an inner and outer nuclear membrane, joined in nuclear pore complexes 
(NPCs), and the underlying nuclear lamina. NPCs tightly regulate entry into the nucleus as they are the 
sole channels through which exchange of (macro)molecules happens. Passive entry through the NPCs 
is limited to molecules less than 10 nm in diameter, thereby excluding passive pDNA entry 
[149,219,220]. In dividing cells, nuclear entry can occur during mitosis, when the nuclear membrane 
breaks down [221]. However, in non-dividing cells, genetic cargo must cross the nuclear envelope 
through the NPCs. In order to promote transnuclear transport through the NPCs, the attachment of 
nuclear localization sequences (NLS) is a traditional strategy. Other methods to enhance nuclear 
translocation include linking of nuclear proteins or small molecule ligands. One example is the binding 
of the glucocorticoid receptor ligand dexamethasone to the plasmid. When dexamethasone binds to 
the glucocorticoid receptor, its NLS is exposed and the entire DNA-ligand-receptor complex can be 
translocated into the nucleus [222,223]. Unfortunately, nuclear entry remains rather poorly studied 
and requires more extensive research to investigate potential improvements [5]. 
Nuclear uptake efficacy is indirectly evaluated in most studies simply by measuring the efficiency of 
gene expression. However, it is necessary to not only measure the final effect of the loaded 
therapeutic agent but also the amount of delivered cargo to the nucleus [196]. Qualitative evaluation 
of nuclear uptake can be provided by CLSM [224,225] and other forms of microscopy such as EM [226]. 
Although these methods give an idea about the presence or absence of nuclear delivery, it is very 
difficult to relate this information to the actual percentage of cargo (from the total amount 
administered) that has been efficiently delivered to the nucleus [220]. 
When quantifying the total amount administered to the nucleus, it is often difficult to differentiate 
between NPls residing in the cytoplasm and NPls residing in the nucleus. Therefore, in order to 
correctly measure nuclear uptake, the nucleus needs to be separated from other cellular components 
before the measurement. Here, it is important to make a distinction between nuclear-membrane 
associated particles and particles that are effectively internalized into the nucleus [220]. Cohen et al. 
compared a density gradient technique to a detergent-based method to isolate the nuclei of 
transfected cells and found that the density gradient procedure yielded nuclei with substantially less 
plasmid attached on the outside of the nuclear membrane. Next, they determined the number of 
plasmids that reach the nucleus after transfection with PEI- or Lipofectamine-based NPls using an 
internally standardized quantitative PCR assay. This method accurately measures the ratio of plasmids 
to a single-copy gene and thus the number of nuclei, thereby directly revealing the amount of plasmids 
per nucleus [227]. In the quantification of nuclear uptake, PCR is the most widely used method since it 
is able to quantify plasmid numbers, has good sensitivity and avoids the need to fluorescently label the 
cargo upon transfection [208,227,228]. Besides PCR, Southern blotting was also used to quantify 
nuclear uptake without the need of using fluorophores [208]. However, efforts are being made to 
introduce techniques that allow a higher throughput. One example is provided by Bishop et al., who 
developed a flow cytometry-based assay to quantify the number of plasmids within the nucleus after 
nuclei isolation. Conversion from fluorescence intensities, measured by flow cytometry, to plasmid 
numbers was performed through calibration via quantitative PCR and fluorimetry. Fluorimetry was 
used to measure the fluorescence of several calibration solutions with a known amount of NAs 
(determined by quantitative PCR). Flow cytometric analysis can provide important information since it 
is able to quantify nuclear uptake on the single cell level [20]. Alternatively, the amount of metallic 
NPls present in the nucleus can be measured by ICP-MS. Huo et al. determined the number of Au-TIOP 
NPls in MCF-7 cells via ICP-MS after cell nuclei were extracted [226]. 
It should be noted however that cellular fractionation and nuclear isolation usually involve 
centrifugation which could lead to inaccurate conclusions due to precipitation of cell-surface bound 
and cytoplasmic NPls within the nuclei pellet [220]. An elegant solution to avoid errors generated by 
cell fractionation and nuclear isolation protocols was proposed by Tammam et al. who assessed 
nuclear delivery in intact cells using FRET fluorometry and microscopy. The authors used Hoechst 
(nuclear staining) as the donor and fluorescein (present on cargo – in this case albumin) as the acceptor 
of the FRET pair and corrected the measurements for cross talk. When the cargo is successfully 
delivered to the nucleus, the dyes are located in close proximity from each other and a FRET signal can 
be measured [229]. However, this assay might be less ideal when using NAs as cargo since Hoechst is 
commonly used to stain DNA and will highly likely interact with NA-cargo outside the nucleus. 
 
Table 1. Overview of techniques with their general pros and cons used to visualize and/or quantify specific intracellular barriers. 
Technique Advantages Limitations 

















Easy to perform 
Single cell measurements 
(semi)quantitative technique 
Requires fluorescent labeling 
No spatial information 
[31,32,78] [100–106] [139] [168,169]  [200]   
Fluorescence 
microscopy 
Easy to perform 




Requires fluorescent labeling 



















Single cell measurements 
Spatial information 
Able to resolve single particles 
Very low throughput 
Extensive sample preparation 
Complex image analysis 
No live-cell imaging possible 
Limited quantitative information 











No spatial information 
        
Fluorimetry Easy to perform Requires fluorescent labeling [78] [27] [138] [129,169]     
Mass spectroscopy Sensitive Destructive sampling required  [79–82] [131] 
[139, 
141–143] 
    [226] 
Blotting Readily available 
Difficult to perform 
Time-consuming 
 [130]   
[181,190, 
191,194] 
 [209] [208] 
ELISA 
Readily available 
Easy to perform 
Time-consuming     [189]    
PCR Sensitive  Time-consuming [97]   [171,172]   [207] [208,227] 
Gel electrophoresis 
Readily available  
Easy to perform 
Unable to measure sample in 
biological environment 
     [199] [206]  
3. CONCLUSIONS  
Non-viral nanoplexes (NPls) loaded with nucleic acids need to overcome several intracellular (IC) 
barriers before they can exert their therapeutic function. Detection and quantification of the 
interaction between NPls and these IC barriers is crucial to gain a better understanding of these events, 
which could lead to the rational development of improved NPls, equipped to conquer the many IC 
hurdles. In this review, we have given an overview of the methods and assays that are currently 
available to study the different IC barriers. A summary of the techniques with their representative 
advantages and limitations is given in Table 1 together with the indication of their applicability to 
evaluate the different IC barriers.  Although there is often a preferred method to study a given barrier, 
the most reliable and in-depth information is gathered by combining complementary assays. In the 
future, it might be interesting to gain more detailed information on the interaction between NPls and 
their barriers through the use of super-resolution microscopy. However, despite the successful use of 
super-resolution techniques in biological sciences to image cellular structures [230], their application 
to probe NPl-cell interactions remains rather limited [102]. Furthermore, efforts should be made in the 
future to allow investigation of NPl-barrier interactions without the need of labeling, since labeling 
strategies might alter the behavior of NPls [231]. Therefore, it is again very important to compare 
results provided by several assays and to think carefully about the advantages and limitation of the 
methods selected to study the interaction of NPls and their IC barriers. 
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